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mTORC1 and CK2 coordinate ternary and eIF4F
complex assembly
Valentina Gandin1,2,3,4,*, Laia Masvidal5,*, Marie Cargnello1,2,3,4,*, Laszlo Gyenis6, Shannon McLaughlan1,2,3,4,
Yutian Cai1,3, Clara Tenkerian1,6, Masahiro Morita3, Preetika Balanathan7, Olivier Jean-Jean8, Vuk Stambolic9,
Matthias Trost10, Luc Furic7, Louise Larose11, Antonis E. Koromilas1,4,6, Katsura Asano12, David Litchﬁeld6,
Ola Larsson5 & Ivan Topisirovic1,2,3,4

Ternary complex (TC) and eIF4F complex assembly are the two major rate-limiting steps in
translation initiation regulated by eIF2a phosphorylation and the mTOR/4E-BP pathway,
respectively. How TC and eIF4F assembly are coordinated, however, remains largely unknown.
We show that mTOR suppresses translation of mRNAs activated under short-term stress
wherein TC recycling is attenuated by eIF2a phosphorylation. During acute nutrient or growth
factor stimulation, mTORC1 induces eIF2b phosphorylation and recruitment of NCK1 to eIF2,
decreases eIF2a phosphorylation and bolsters TC recycling. Accordingly, eIF2b mediates the
effect of mTORC1 on protein synthesis and proliferation. In addition, we demonstrate a
formerly undocumented role for CK2 in regulation of translation initiation, whereby CK2
stimulates phosphorylation of eIF2b and simultaneously bolsters eIF4F complex assembly via
the mTORC1/4E-BP pathway. These ﬁndings imply a previously unrecognized mode of
translation regulation, whereby mTORC1 and CK2 coordinate TC and eIF4F complex
assembly to stimulate cell proliferation.
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M

essenger RNA (mRNA) translation plays a major role in
homeostasis, whereas its dysregulation underpins a
variety of pathological states including cancer,
metabolic syndrome and neurological disorders1. Activation of
mRNA translation requires rapid and highly coordinated
assembly of the eukaryotic translation initiation factor 4F
(eIF4F) complex composed of cap-binding subunit eIF4E, large
scaffolding protein eIF4G and DEAD box helicase eIF4A, and the
ternary complex (TC) comprised of eIF2, GTP and initiator
)2. eIF4F recruits mRNA to the ribosome,
tRNA (tRNAMet
i
whereas TC delivers tRNAMet
(ref. 2). Mammalian/mechanistic
i
target of rapamycin complex 1 (mTORC1) integrates a
number of stimuli including nutrients, growth factors
and hormones to bolster protein synthesis3. mTORC1
phosphorylates and inactivates the eIF4E-binding proteins
(4E-BPs), which leads to their dissociation from eIF4E, thereby
allowing eIF4E:eIF4G interaction and eIF4F complex assembly1.
How mTORC1-dependent stimulation of eIF4F assembly is
coordinated with TC recycling, however, remains largely
underexplored.
eIF2 is a heterotrimer that comprises eIF2a, b and g subunits2.
, eIF2-bound
After recognition of the start codon by tRNAMet
i
GTP is hydrolyzed to GDP and the TC complex is recycled by the
guanine nucleotide exchange factor (GEF) eIF2B, which converts
eIF2:GDP to eIF2:GTP2. eIF2a phosphorylation, which is induced
by eIF2a kinases (protein kinase RNA-like endoplasmic
reticulum kinase (PERK), protein kinase RNA-activated (PKR),
general control nonderepressible 2 (GCN2) and haem-regulated
inhibitor kinase) in response to various types of stress including
endoplasmic reticulum stress, amino-acid unavailability, haem
deﬁciency and viral infection, inhibits GEF function of eIF2B,
thereby suppressing TC recycling and limiting TC levels1,2. This
leads to suppression of global protein synthesis, with concomitant
increase in translation of mRNAs harbouring inhibitory upstream
open reading frames (uORF mRNAs) that encode stress-induced
transcriptional regulators such as activating transcription factor 4
(ATF4) and CCAAT-enhancer-binding protein homologous
protein (CHOP)4. Persistent mTORC1 activation is thought to
induce chronic endoplasmic reticulum stress and perturbs AKT
signalling, resulting in secondary elevation in eIF2 kinase activity
and eIF2a phosphorylation4. However, it is largely unknown how
mTORC1 affects eIF2a phosphorylation during acute activation
of the translational machinery by nutrients, growth factors or
hormones (for example, insulin).
Results
mTOR decreases phospho-eIF2a-stimulated translation.
Recently, a transcriptome-wide catalogue of mRNAs whose
translation is upregulated after induction of eIF2a phosphorylation by acute endoplasmic reticulum stress (hereafter referred to
as ‘eIF2a-sensitive’ mRNAs) was determined5. To investigate the
effects of changes in mTOR signalling on translation of ‘eIF2asensitive’ mRNAs5, we used the polysome proﬁling technique,
wherein mRNAs are separated based on the numbers of
ribosomes they bind using a sucrose gradient and
ultracentrifugation, followed by analysis of the changes in
translation and cytosolic mRNA levels on a transcriptome-wide
scale6. Transcriptome-wide polysome proﬁling in MCF7 cells
revealed that induction of mTOR signalling by 4 h insulin
treatment coincides with translational suppression of ‘eIF2asensitive’ mRNAs5, as compared with those whose translation
was determined to be independent of eIF2a phosphorylation5
(background mRNAs; Fig. 1a,b; Po5.2e  12). In turn, addition
of the active-site mTOR inhibitor torin1 (ref. 7) to insulin-treated
cells selectively induced translation of ‘eIF2a-sensitive’
2

mRNAs (Fig. 1a,b; Po3.7e  16). These effects of modulation
of mTOR signalling on translation of ‘eIF2a-sensitive’
mRNAs were not caused by the changes in cytoplasmic mRNA
levels (Fig. 1b).
mTOR affects phospho-eIF2b and phospho-eIF2a levels.
Insulin induced mTORC1 signalling as illustrated by elevated
phosphorylation of 4E-BPs and the S6 kinase (S6K) substrate
ribosomal protein S6 (rpS6) as compared with control
serum-starved cells, which was reverted by the allosteric mTOR
inhibitor rapamycin or active-site mTOR inhibitor (KU-0063794
and torin1) (Fig. 1c; compare lanes 2 and 7 with lanes 3–5 and
8–10, respectively). In addition, insulin decreased phospho-eIF2a
levels as compared with control serum-starved cells, and cells
stimulated with insulin in the presence of mTOR inhibitors
(Fig. 1c; compare lanes 2 and 7 with lanes 3–5 and 8–10,
respectively). In stark contrast to effects of treatments on eIF2a
phosphorylation, eIF2b phosphorylation on serine 2 (Ser2) was
enhanced by insulin relative to the control, and diminished
when cells were stimulated with insulin in the presence of
mTOR inhibitors (Fig. 1c; compare lanes 2 and 7 with lanes 3–5
and 8–10, respectively). Phosphorylation of eIF2a stimulates
ATF4 mRNA translation and consequently upregulates ATF4
protein levels8. Although the effects of insulin and mTOR
inhibitors on eIF2a phosphorylation were detected after 30 min,
neither insulin nor mTOR inhibitors exerted a major impact on
ATF4 protein expression at this time point (Fig. 1c; compare lane
1 with lanes 2–5). Even though these results appear surprising,
they are consistent with several studies showing that under a
number of experimental conditions that favour eIF2a
phosphorylation including ultraviolet irradiation, endoplasmic
reticulum and osmotic stress, induction of ATF4 protein
expression is either delayed or absent9–11. Accordingly, insulin
downregulated ATF4 protein levels relative to the control, which
was reversed by mTOR inhibitors after 4 h (Fig. 1c; lanes 6–10).
Under these conditions, insulin inhibited ATF4 mRNA
translation as illustrated by the shift of ATF4 mRNA towards
lighter polysomes, as compared with control serum-starved cells
or cells that were stimulated with insulin in the presence of torin1
(Fig. 1d, left panel). In contrast, distribution of b-actin mRNA
across the polysomes was essentially unchanged between the
treatments (Fig. 1d, right panel). These ﬁndings show that under
these conditions, mTOR activation leads to inhibition of ATF4,
but not b-actin mRNA translation, which is consistent with
results obtained from the transcriptome-wide polysome-proﬁling
study (Fig. 1b). Therefore, similarly to the establish selectivity
of the stimulatory effects of mTOR on translation of terminal
oligopyrimidine (TOP) and long and structured 50 -untranslated
region (UTR) harbouring mRNAs12, mTOR also appears to
selectively inhibit translation of mRNAs that are upregulated
under conditions wherein eIF2a phosphorylation is increased.
Although insulin slightly induced steady-state ATF4 mRNA levels
compared with torin1, these effects were not signiﬁcant (Fig. 1e),
thereby indicating that the changes in ATF4 protein expression
observed between treatments are largely caused by the changes in
translation and not by the upstream steps in the gene expression
pathway (for example, transcription or mRNA stability).
Therefore, short-term (4 h) inhibition of mTOR signalling
correlates with reduction in phospho-eIF2b levels, increase in
phospho-eIF2a levels and concomitant translational activation of
‘eIF2a-sensitive’ mRNAs including ATF4. Since the latter
ﬁndings were based on a single-cell line, we tested the effects of
serum withdrawal and repletion on phosphorylation of eIF2b and
eIF2a in the presence of mTOR inhibitors in parallel in HEK293E
and MCF7 cells. A 30-min serum stimulation induced mTOR
activity in HEK293E and MCF7 cells as demonstrated by
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Figure 1 | mTOR stimulates eIF2b phosphorylation, decreases eIF2a phosphorylation and represses translation of mRNAs that are upregulated by
phospho-eIF2a. (a,b) MCF7 cells were serum starved for 16 h followed by 4-h stimulation with insulin (4.2 nM; Ins) in the presence of a vehicle (DMSO) or
torin1 (250 nM). (a) Absorbance proﬁles (254 nm) of cytosolic extracts loaded onto 5–50% sucrose gradients and sedimented by ultracentrifugation.
mRNA was isolated from fractions containing 43 ribosomes (box) and analysed in parallel with cytoplasmic mRNA using microarrays (see Methods).
Positions of small (40S) and large (60S) ribosome subunits, monosomes (80S) and polysomes in the gradients are indicated. AU, absorbance units.
(b) Transcriptome-wide effects of 4-h insulin and insulin þ torin1 treatments on the translatome (polysome associated; upper panel) or steady-state
cytoplasmic mRNA levels (lower panel). Presented are mRNAs whose translation is upregulated by eIF2a phosphorylation (‘eIF2a sensitive’, red curve) and
those that are not affected under conditions where eIF2a phosphorylation is stimulated (background; black curve) according to the study of Baird et al.5.
Wilcoxon P values contrasting fold changes for eIF2a-regulated to background mRNAs are indicated. The experiment was carried out in four independent
replicates. (c) MCF7 cells were treated as in b for the indicated time periods. In addition to torin1, allosteric mTOR inhibitor rapamycin (RAP; 50 nM) and
active-site mTOR inhibitor KU-0063794 (KU; 3 mM) were used. Phosphorylation and expression levels of indicated proteins were monitored by western
blotting. b-Actin served as a loading control. Experiments were repeated in at least two independent replicates and quantiﬁed by densitometry
(Supplementary Fig. 9). (d,e) MCF7 cells were serum starved for 16 h (Starved) and then treated and fractionated as in b. Relative amounts of ATF4 and
b-actin mRNA in polysome fractions (d) or cytosolic extracts (for steady-state mRNA measurements) (e) were determined by reverse transcription–
quantitative PCR (RT–qPCR). Position of monosome (80) and polysomal fractions are shown. (d,e) S.d.’s and interaction (treatment and fraction) P values
from a two-way analysis of variance (ANOVA) using means of two independent experiments each consisting of technical replicates are indicated.

increased S6K phosphorylation, which coincided with increased
eIF2b phosphorylation and reduced phospho-eIF2a levels relative
to the control (Fig. 2a; compare lanes 1 and 2). These effects were
largely diminished when cells were stimulated with serum in the

presence of rapamycin or torin1 (Fig. 2a; compare lane 2 versus
lanes 3–4). Therefore, observed correlation between changes in
mTOR activity and phosphorylation status of eIF2a and eIF2b is
not limited to a single-cell line.
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Figure 2 | mTOR and CK2 inhibitors suppress eIF2b phosphorylation, increase phospho-eIF2a levels and interfere with eIF4F complex assembly.
(a) HEK293E or MCF7 cells were serum starved for 16 h and then stimulated with 10% serum (fetal bovine serum, FBS) in the presence of a vehicle
(DMSO), rapamycin (50 nM) or torin1 (250 nM) for 30 min. Phosphorylation status and levels of indicated proteins were monitored by western blotting.
b-Actin served as a loading control. (b) HEK293E cells were serum starved for 16 h and then stimulated for 30 min with serum (FBS; 10%) in the presence
of a vehicle (DMSO), 250 nM torin1, 15 or 50 mM CX-4945. Phosphorylation and expression levels of indicated proteins were monitored by western
blotting. b-Actin served as a loading control. (c) Extracts of HEK293E cells treated as in b were subjected to m7GTP cap pull down (see Methods). Levels
and phosphorylation status of indicated proteins in the pulled down material (25%) and inputs (10%) were determined by western blotting. b-Actin served
to exclude contamination of m7GTP cap pull downs (for example, non-speciﬁc binding to the agarose beads) and as a loading control for inputs. Parallel
results were obtained in MCF7 and HCT116 cells (Supplementary Fig. 1a,b). (d) Expression of HA-CK2a in U2OS cells was induced by tetracycline
withdrawal (doxycycline was used at 1.5 mg ml  1 to suppress expression of CK2 subunits in control cells). Cells were starved for 16 h after which cells were
stimulated by 10% serum (FBS) in the presence of a vehicle (DMSO), 250 nM torin1, 50 mM CX-4945 or a combination thereof for the indicated time
period. (e) HCT116 PTEN þ / þ or PTEN  /  cells were treated with the indicated concentration of CX-4945 for 1 h in the presence of 10% serum (FBS).
(f) Cells described in e were incubated with DMSO or torin1 (250 nM) for 1 h. (d–f) Expression levels and phosphorylation status of indicated proteins were
monitored by western blotting. b-Actin served as a loading control. Experiments in this panel were repeated at least two times independently and the
representative results are shown. Where appropriate, quantiﬁcation was performed using densitometry (Supplementary Fig. 9).

CK2 phosphorylates eIF2b and stimulates eIF4F assembly. It
has been reported that Casein kinase 2 (CK2), which is stimulated
by insulin and serum13,14 phosphorylates eIF2b on serines 2 and
67 (Ser2 and Ser67), and eIF2b phosphorylation at these sites may
stimulate global mRNA translation and cell proliferation15. We
therefore investigated whether CK2 plays a role in the apparent
correlation between induction of eIF2b phosphorylation and
4

stimulation of mTOR signalling by serum and insulin. Starved
HEK293E cells were serum stimulated in the presence of a vehicle
(dimethylsulphoxide, DMSO), torin1 or CK2 inhibitor CX-4945
for 30 min. Both torin1 and CX-4945 reduced serum-induced
phosphorylation of eIF2b in HEK293E cells, which was paralleled
by increased eIF2a phosphorylation, relative to the control
(Fig. 2b; compare lane 1 with lanes 2–4). In addition, both the
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inhibitors reduced 4E-BP1 phosphorylation (Fig. 2b; compare
lane 1 with lanes 2–4), although higher concentration of CX-4945
(50 mM) was required for strong inhibition of eIF2b and 4E-BP1
phosphorylation and induction of eIF2a phosphorylation as
compared with rpS6 phosphorylation (15 mM) (Fig. 2b; lane 3
versus 4). Consistent with inhibiting 4E-BP1 phosphorylation,
CX-4945 impaired eIF4F assembly as illustrated by reduced
eIF4E:eIF4G1 association and increased eIF4E:4E-BP1 binding
relative to the control, and this effect was more pronounced when
a higher concentration of CX-4945 (that is, 50 mM) was used
(Fig. 2c, compare lane 1 with lanes 2–4). Equivalent results were
observed in MCF7 cells, whereby torin1 and CX-4945 (15 and
50 mM) reduced eIF2b phosphorylation and disrupted eIF4F
complex (Supplementary Fig. 1a). Moreover, similar effects of
50 mM CX-4945 on the mTORC1 signalling and eIF4F complex
assembly were observed in HCT116 cells (Supplementary
Fig. 1b). Collectively, these ﬁndings demonstrate that CK2
regulates not only eIF2b phosphorylation but also eIF4F
complex assembly. Next, we sought to determine the
relationship between CK2 and mTOR in regulating eIF2b
phosphorylation and eIF4F complex assembly. We ﬁrst
employed U2OS cells in which CK2a-HA/Myc-b expression
and consequently CK2 activity are increased by removal of
doxycycline from the growth media16 (Fig. 2d). Induction of
CK2a-HA/Myc-b expression increased eIF2b phosphorylation,
while exhibiting minimal effects on 4E-BP1 and rpS6
phosphorylation, which was expected as these experiments were
carried out under full serum conditions wherein mTORC1
activity is high (Fig. 2d; compare lane 1 versus 2 and 6 versus 7).
In turn, CX-4945 decreased phosphorylation of eIF2b as well as
4E-BP1 and rpS6 after 2 and 7 h (Fig. 2d; compare lane 2 versus 3
and 7 versus 8). Increase in CK2 activity engendered by
overexpression of its subunits did not conspicuously affect the
ability of torin1 to inhibit phosphorylation of 4E-BP1 and rpS6
(Fig. 2d; compare lane 2 versus 4 and 7 versus 9). In contrast, the
effects of torin1 on eIF2b phosphorylation were attenuated in
cells in which CK2a-HA/Myc-b overexpression was induced,
whereby torin1 inhibited eIF2b phosphorylation after 7 h but not
after 2 h (Fig. 2d; compare lane 2 versus 4 and 7 versus 9). These
ﬁndings suggest that CK2 directly phosphorylates eIF2b, while
stimulating 4E-BP1 phosphorylation via mTORC1, whereby the
effects of mTOR inhibitors on eIF2b phosphorylation are
mitigated by CK2a-HA/Myc-b overexpression.
mTORC1 phosphorylates eIF2b independently of CK2. CK2
phosphorylates PTEN resulting in its inactivation and consequent
upregulation of mTOR activity17,18. Therefore, to further assess
the hierarchy of mTORC1 and CK2 in regulation of eIF2b
phosphorylation, isogenic HCT116 PTEN þ / þ and PTEN  / 
cells19 were treated with CX-4945 and torin1. Although the
primary CK2 phospho-acceptor sites on PTEN were mapped to
Ser370/385 (ref. 17), due to limited availability of corresponding
antibodies, we monitored the effects of CX-4945 on
phosphorylation of Ser380/Thr382/383, which are also CK2
responsive20. In PTEN þ / þ cells, CX-4945 strongly reduced
PTEN phosphorylation and mTOR signalling as judged by
reduction in rpS6 and 4E-BP1 phosphorylation (Fig. 2e; compare
lane 1 with lanes 2–4), whereas in PTEN  /  cells, there was no
apparent effect of CX-4945 on mTOR signalling (Fig. 2e; compare
lane 5 with lanes 6–8). Whereas 1-h CX-4945 treatment reduced
eIF2b phosphorylation and induced phospho-eIF2a levels in a
dose-dependent manner in PTEN þ / þ cells, these effects of
CX-4945 were largely absent in PTEN  /  cells (Fig. 2e; compare
lanes 2–4 with 6–8). CX-4945 however suppressed eIF2b
phosphorylation and increased phospho-eIF2a levels after 7 h,

which was not accompanied by a reduction in mTOR signalling
(Supplementary Fig. 1c). In contrast to eIF2b phosphorylation,
PTEN status did not have a major impact on the effects of
CX-4945 on another bona ﬁde CK2 substrate eEF1d inasmuch as
CX-4945 inhibited phosphorylation of eEF1d to a comparable
extent in both PTEN  /  and PTEN þ / þ cells after 1 h (Fig. 2e;
compare lanes 2–4 to 6–8). Conversely, torin1, which inhibits
mTORC1 downstream of PTEN21, reduced phosphorylation of
4E-BP1 and rpS6, irrespective of the PTEN status in the cell
(Fig. 2f; lanes 2 and 4 versus lanes 1 and 3). Moreover, in both cell
lines, eIF2b phosphorylation was suppressed to a comparable
extent and this coincided with increased eIF2a phosphorylation
(Fig. 2f; lanes 2 and 4 versus lanes 1 and 3). In turn, torin1 did not
elicit a major effect on the phosphorylation of eEF1d (Fig. 2f;
lanes 1–4). These ﬁndings indicate that in the absence of mTOR
inhibition, the effects of CK2 on eIF2b are delayed. To further
establish the role of mTOR signalling in phosphorylation of
eIF2b, we used TSC2  /  mouse embryonic ﬁbroblasts (MEFs)
wherein mTOR is activated by the loss of a negative upstream
regulator TSC1/2 (ref. 22). Similarly to cells lacking PTEN, torin1,
but not CX-4945, inhibited eIF2b phosphorylation on Ser2
(Supplementary Fig. 1d,e). These data suggest that analogous to
the attenuation of the effects of mTOR inhibition on eIF2b
phosphorylation observed in U2OS cells overexpressing CK2
(Fig. 2d), lack of ability of CX-4945 to suppress mTOR mitigates
its inhibitory effects on eIF2b phosphorylation (Fig. 2e;
Supplementary Fig. 1e). These results suggest that CK2 and
mTOR may collaboratively regulate eIF2b phosphorylation on
Ser2. Inability of CK2 inhibitors to downregulate mTOR
signalling in PTEN  /  and TSC  /  cells appears to coincide
with delayed inhibition of eIF2b phosphorylation. Moreover, in
TSC  /  MEFs, in which serum starvation does not result in a
marked mTOR inhibition, removal of serum had much lesser
effect on eIF2b phosphorylation as compared with TSC þ / þ
MEFs (Supplementary Fig. 1f). This shows that efﬁcient
suppression of eIF2b phosphorylation in response to CK2
inhibitors and serum withdrawal requires downregulation of
mTOR signalling, thereby suggesting that at least under certain
conditions mTOR may phosphorylate eIF2b independently of
CK2. Although sequences surrounding Ser2 and Ser67 in eIF2b
do not correspond to a presumed mTOR consensus23, eIF2b
contains a putative TOS motif (Supplementary Fig. 2a,b). The
TOS motif is required for binding to raptor and recruitment of
mTORC1 substrates24. Indeed, mTORC1 phosphorylated eIF2b
in in vitro kinase assay, and this effect was reduced when
mTORC1 was inhibited (by serum starvation or torin1 treatment
of cells from which mTORC1 was isolated), when Ser2 and
Ser67 were substituted with alanines (eIF2b S(2,67)A), or
when TOS motif was disrupted (phenylalanine 89 substituted
with alanine; TOS mutant) (Supplementary Fig. 2c–e). Reduced
phosphorylation of eIF2b mutants did not stem from the
inadvertent effects of mutations on the secondary structure of
the protein as illustrated by indistinguishable far-ultraviolet
circular dichroism spectra of wild-type (WT) and mutant eIF2b
proteins (Supplementary Fig. 2f). CK2 was not detected in the
mTORC1 complex used in in vitro kinase assay (Supplementary
Fig. 2g). This excluded the possibility that eIF2b was
phosphorylated due to the contamination of mTORC1 in vitro
kinase assay reactions with CK2. In HEK293E cells, eIF2b
co-immunoprecipitated with raptor when mTOR was activated
by serum stimulation (Supplementary Fig. 2h). Disruption of
putative eIF2b TOS motif abolished raptor:eIF2b interaction
(Supplementary Fig. 2i), but not eIF2b:CK2 association
(Supplementary Fig. 2j). Notably, although the indistinguishable
amounts of CK2a were immunoprecipitated by TOS mutant and
other eIF2b variants, TOS mutant was not phosphorylated in
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rictor expression did not exert a signiﬁcant effect on phosphoeIF2b levels, but as expected decreased phosphorylation of the
mTORC2 target AKT as compared with control (Fig. 3a,b). Either
raptor or rictor depletion induced phospho-eIF2a (Fig. 3a,b), thus
indicating that mTORC1 and mTORC2 inﬂuence eIF2a
phosphorylation by distinct mechanisms likely as a response to
different stimuli (see discussion).
Phospho-eIF2b suppresses translation of ATF4 mRNA. We
next determined whether eIF2b phosphorylation plays a role in
translation regulation. Although initial reports suggested that
eIF2b may be dispensable for translation25,26, subsequent studies
demonstrated that eIF2b facilitates tRNA binding to eIF2
(ref. 27). Overexpression of non-phosphorylatable S(2,67)A and
TOS eIF2b mutants increased eIF2a phosphorylation relative to
WT eIF2b even in serum-fed cells and this effect was comparable
with endoplasmic reticulum stress inducer thapsigargin (Fig. 3c;
compare lanes 2, 4 and 5 with lanes 1 and 3). Induction of ATF4
protein levels by serum starvation was mitigated in S(2,67)D
eIF2b mutant-expressing cells, as compared with control cells and
cells expressing WT, S(2,67)A or TOS eIF2b mutants (Fig. 3d;
compare lane 5 with lanes 1–4). Similarly to thapsigargin,
S(2,67)A or TOS eIF2b mutants induced expression of a
luciferase reporter mRNA bearing the 50 UTR of human ATF4
(p50 UTR ATF4-ﬁreﬂy luciferase)28 (Fig. 3e). Moreover, addition
of recombinant eIF2b WT, but not S(2,67)A or TOS mutants,
increased mRNA translation in rabbit reticulocyte lysate (RRL)
until amounts of eIF2b exceeding levels of eIF2a and eIF2g were
reached (Supplementary Fig. 3a). To conﬁrm these results, RRL
was depleted of eIF2 and reconstituted by adding equimolar
amounts of eIF2a/eIF2g and increasing amounts of recombinant
eIF2b WT, S(2,67)A or TOS mutants (Supplementary Fig. 3b).
Although all three eIF2b variants were capable of supporting
basal levels of mRNA translation as illustrated by higher
translational activity in all reconstituted RRLs, as compared
with eIF2-depleted RRL, only WT eIF2b increased mRNA
translation in a concentration-dependent manner (Supplementary Fig. 3c). Importantly, recombinant WT, but not S(2,67)A or
TOS eIF2b mutants, were phosphorylated on Ser2 in RRL
(Supplementary Fig. 3d), which is consistent with previous
reports showing CK2 activity in RRL29. Cells expressing S(2,67)A
or TOS eIF2b mutants exhibited lower global protein synthesis
relative to WT or phosphomimetic S(2,67)D eIF2b mutant, as
monitored by 35S-labelling (Fig. 3f). Monitoring absorbance
proﬁles (254 nm) of cytosolic HEK293E extracts separated by
ultracentrifugation on a 15–35% sucrose gradient further
conﬁrmed that global translation is reduced under conditions
where eIF2b cannot be phosphorylated, as evidenced by an

increase in 80S monosome peak in S(2,67)A and TOS eIF2b
mutant- versus WT-expressing cells (Supplementary Fig. 3e).
These data show that eIF2b phosphorylation correlates with
decreased translation of mRNAs harbouring uORFs (for example,
ATF4) while bolstering global protein synthesis.
Phospho-eIF2b bolsters TC recycling and protein synthesis. We
next investigated whether eIF2b mediates effects of mTORC1 on
eIF2a phosphorylation and mRNA translation. To avoid
interference of the endogenous eIF2b, and since depletion of
eIF2b reduced cell viability30 (Supplementary Fig. 4a), we ﬁrst
overexpressed FLAG-tagged WT, S(2,67)A, TOS and S(2,67)D
eIF2b mutants in HEK293E cells and then depleted endogenous
eIF2b by short hairpin RNA (shRNA; Supplementary Fig. 4b).
In serum-stimulated cells, eIF2b phosphorylation was detected in
vector/scrambled shRNA-infected control cells, which still
express endogenous eIF2b and cells expressing exogenous WT
eIF2b, but not in cells expressing exogenous mutant forms of
eIF2b with mutated phospho-acceptor sites to generate
non-phosphorylatable (S(2,67)A) or phosphomimetic (S(2,67)D)
mutants or disrupted TOS motif (TOS; Fig. 3g; compare lanes 1–2
versus 3–5; Supplementary Fig. 4c). Phospho-eIF2a and ATF4
protein levels were higher in non-phosphorylatable S(2,67)A and
TOS eIF2b mutants, as compared with control, WT and
phosphomimetic S(2,67)D eIF2b mutant-expressing cells
(Fig. 3g; compare lanes 3–4 versus 1–2 and 5). Although
mTOR activity was comparably reduced by torin1 across all
cell lines as monitored by inhibition of S6K phosphorylation
(Fig. 3g; compare lanes 2–5 with lanes 6–10), only S(2,67)D eIF2b
mutant attenuated induction of eIF2a phosphorylation and
dampened increase in ATF4 expression (Fig. 3g; compare lanes
6–9 with 10). Neither serum-stimulated nor torin1-treated
cells (4 h) exhibited major differences in steady-state ATF4
mRNA levels (Fig. 3h), thereby suggesting that the observed
effects on ATF4 protein levels after 4 h treatments most likely
occur at the level of translation. These results demonstrate that
eIF2b phosphorylation plays a major role in mediating
mTOR-dependent downregulation of ATF4 protein synthesis
and stimulation of global mRNA translation. Since we observed
that phosphorylation status of eIF2b appears to affect eIF2a
phosphorylation, we set out to determine the role of eIF2b
phosphorylation in TC recycling using HEK293E cells, which
express eIF2b variants and are depleted of endogenous eIF2b
(Supplementary Fig. 4b). After 30-min serum stimulation,
S(2,67)A and TOS eIF2b mutants immunoprecipitated
as compared with WT
drastically lower amounts of tRNAMet
i
and S(2,67)D eIF2b mutant (Fig. 4a; compare lanes 10–11 with
lanes 9 and 12; Supplementary Fig. 4d). In turn, rapamycin and

Figure 3 | eIF2b phosphorylation by mTORC1 coincides with dephosphorylation of eIF2a. HEK293E cells infected with scrambled shRNA (Scr) (a,b),
raptor (a) or rictor (b) shRNA were serum starved (16 h) and then stimulated with 10% serum (FBS; 30 min). (c,d) HEK293E cells were co-transfected with
shown FLAG-eIF2b variants, p50 UTR ATF4-ﬁreﬂy (ATF4 uORFs) and renilla luciferase reporter constructs and treated with 1 mM thapsigargin (TG; 1 h)
(c) or serum starved (d). (e) Luciferase activity in cells described in c and d was determined by chemiluminescence. Mean relative light units (RLU) of
individual luciferase (middle and right panel) or ratio thereof (left panel) are shown. Data of three independent experiments were log2 transformed,
normalized per replicate and to the mean of control condition, and shown as means and s.d.’s. P values from one-way analysis of variance (ANOVA) are
indicated. (f) HEK293E cells were serum starved (16 h) and followed by 10% serum stimulation (FBS) in the presence of a vehicle (DMSO) or torin1
(250 nM) for 3 h. Global protein synthesis was monitored by 35S-Met/Cys incorporation. Data from three independent experiments were log2
transformed, normalized per replicate and to the mean of the control condition, and shown as means±s.d. P values from one-way ANOVAs are indicated.
(g) HEK293E cells infected with empty vector þ scrambled shRNA (control) or stably expressing indicated eIF2b variants and depleted of endogenous
eIF2b (Supplementary Fig. 4b; Methods) were serum starved (16 h), followed by 10% serum (FBS) stimulation in the presence of a vehicle (DMSO) or
torin1 (250 nM) for 30 min or 4 h. (h) Steady-state ATF4 mRNA levels after 4 h treatments as described in g were determined by RT–qPCR and normalized
over b-actin values. Means from two independent experiments, each in technical triplicate were log2 transformed, normalized per replicate and to the
control, and are shown as means with s.d.’s. The P value from a one-way ANOVA across all treatments is indicated. (a–d,g) Experiments were repeated at
least two times independently and representative results are shown. (a–d,g) Levels and phosphorylation status of indicated proteins were monitored by
western blotting. b-Actin was a loading control. Densitometry is shown in Supplementary Fig. 9. Endog, endogenous; exog, exogenous.
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Figure 4 | eIF2b phosphorylation stimulates TC recycling. (a) HEK293E cells that stably express exogenous WT or indicated FLAG-eIF2b mutants in
which endogenous eIF2b was depleted by shRNA (Supplementary Fig. 4b; Methods) were serum starved for 16 h, stimulated with serum (10%) for 30 min
and subjected to FLAG immunoprecipitation (IP). Inputs (10%; Supplementary Fig. 4c) and quantity of immunoprecipitated proteins (25%) was determined
by western blotting. The amount of tRNAMet
in the immunoprecipitated material was monitored by semi-quantitative reverse transcriptase–PCR (sqRT–
i
PCR). tRNALys was used as a negative control. (b) Cells described in a that express WT or S(2,67)D FLAG-eIF2b were serum starved for 16 h and then
stimulated with 10% serum (fetal bovine serum, FBS) in the presence of a vehicle (DMSO), rapamycin (50 nM) or torin1 (250 nM) for 30 min. Lysates were
immunoprecipitated with an anti-FLAG antibody. The quantity of tRNAMet
and tRNALys in immunoprecipitates and input (10%) was analysed by sqRT–PCR,
i
whereas the levels of indicated protein were determined by western blotting. (c) Cells described in (a) were serum starved for 16 h and then stimulated
with 10% serum (FBS) for 30 min in the presence of a vehicle (DMSO) or torin1 (250 nM). Immunoprecipitations were carried out as described in a. The
amount of indicated proteins in FLAG-eIF2b immunoprecipitated material and inputs (10%) was monitored by western blotting. (b,c) Western blotting
experiments were performed in independent duplicates and the representative results are shown. sqRT–PCR (n ¼ 3) results were independently conﬁrmed
using quantitative RT–PCR (Supplementary Fig. 4d,e).

torin1 prevented serum-induced increase in tRNAMet
binding to
i
WT eIF2b, while not exerting a major effect on the amount of
in immunoprecipitates from S(2,67)D eIF2b-expressing
tRNAMet
i
cells (Fig. 4b; compare lanes 4–5 and 6–7 in the top panel,
Supplementary Fig. 4e). eIF2a phosphorylation inhibits GEF
activity of eIF2B and eIF2:eIF2B dissociation2. We therefore
investigated whether eIF2b phosphorylation affects eIF2:eIF2B
association by monitoring the amount of eIF2Bd, which mediates
recruitment of eIF2B to eIF2 (ref. 31) by immunoprecipitating
cell lysates with an anti-FLAG antibody. In serum-stimulated
cells, the amount of eIF2Bd was higher in immunoprecipitated
material from S(2,67)A and TOS eIF2b mutant-expressing cells,
as compared with those expressing WT and S(2,67)D eIF2b
mutant (Fig. 4c). In turn, torin1 increased WT eIF2b:eIF2Bd, but
not S(2,67)D eIF2b:eIF2Bd association, to the levels observed in
S(2,67)A and TOS eIF2b mutant-expressing cells (Fig. 4c;
compare lane 2 with lane 6 versus lane 5 with lane 9).
Expression of exogenous eIF2b variants did not conspicuously
affect mTORC1 signalling (for example, Fig. 3g), thereby
indicating that these effects were mediated by eIF2b and not
8

other mTORC1 substrates. Altogether, these ﬁndings show that
eIF2b phosphorylation decreases eIF2a phosphorylation and
binding while stimulating dissociation of
increases eIF2:tRNAMet
i
eIF2B from eIF2. This suggests that phospho-eIF2b stimulates TC
recycling. Phosphorylation status of eIF2a is determined via the
action of eIF2a kinases (for example, PKR and PERK) and
phosphatases (for example, protein phosphatase 1 (PP1))4.
Notwithstanding that our results show that phosphorylation
status of eIF2b affects phospho-eIF2a levels (Fig. 3c,d,g;
Supplementary Figs 4c and 5a); PERK and PKR activation
status as monitored by Thr981 and Thr446 appeared to be largely
unaffected by eIF2b WT or mutant proteins (Supplementary
Fig. 5a). Moreover, although concentration-dependent induction
of PERK phosphorylation by thapsigargin was comparable
between WT and S(2,67)D eIF2b mutant, corresponding
induction of ATF4 protein expression was seemingly reduced in
S(2,67)D eIF2b mutant, relative to WT eIF2b-expressing cells
(Supplementary Fig. 5b). These observations suggest that the
effects of eIF2b on eIF2a phosphorylation are not likely to be
mediated by PERK or PKR.
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Figure 5 | Phospho-eIF2b recruits NCK1 to eIF2 and mediates the effects of mTORC1 on proliferation. (a) HEK293E cells were depleted of serum for
16 h and then stimulated with 10% serum (fetal bovine serum, FBS) in the presence of a vehicle (DMSO), rapamycin (50 nM) or torin1 (250 nM) for
30 min. Anti-eIF2b antibody immunoprecipitates (25%) and corresponding inputs (10%) were analysed by western blotting using indicated antibodies.
H.C., heavy chains (b,c) HEK293E cells were transfected with the indicated eIF2b constructs, serum starved for 16 h and stimulated with 10% serum
(FBS) in combination with a vehicle (DMSO) (b) or torin1 (250 nM) (c). Anti-FLAG antibody immunoprecipitates (25%) and corresponding inputs (10%)
were analysed by western blotting using indicated antibodies. (d) HEK293E cells expressing indicated eIF2b constructs were transfected with a control,
scrambled siRNA (Scr) or siRNA targeting NCK1 (siNCK1), serum starved and then stimulated with 10% serum in the presence of a vehicle (DMSO) or
torin1 (250 nM) for 30 min. Expression and phosphorylation status of indicated proteins were monitored by western blotting. b-Actin served as a loading
control. Experiments in a–d were carried out two times independently. (e) HEK293E cells expressing indicated eIF2b variants in which endogenous eIF2b
was depleted by shRNA (Supplementary Fig. 4b) were treated with a vehicle (DMSO) or torin1 (250 nM) for indicated times. Proliferation was measured
by 5-bromo-20 -deoxyuridine (BrdU) incorporation, and the results are represented as mean absorbance at 370 nm±s.d. from three independent
experiments, each consisting of a technical duplicate.

Phospho-eIF2b recruits NCK1 to eIF2. eIF2b binds the noncatalytic region of tyrosine kinase adaptor protein 1 (NCK1),
which has been implicated in recruitment of PP1 to eIF2 leading to
eIF2a dephosphorylation32. Consistently, we observed that the
levels of NCK1 are reduced in eIF2-depleted RRL (Supplementary
Fig. 3b, left panel), and although it has been suggested that eIF2b
phosphorylation may negatively regulate its binding to NCK1
using in vitro binding assay33, insulin, which we show strongly
increases phosphorylation of eIF2b, stimulates recruitment of
NCK1 to ribosomes34. To address the potential role of NCK1 in
mediating the effects of phospho-eIF2b on eIF2a phosphorylation,
immunoprecipitations were carried out in parental HEK293E
cells or in HEK293E cells expressing WT or eIF2b mutants.
Endogenous eIF2b and NCK1 were co-immunoprecipitated in

serum-stimulated cells, but not in serum-starved cells (Fig. 5a;
compare lanes 1 and 2), wherein eIF2b:NCK1 interaction
was disrupted by mTOR inhibitors (Fig. 5a; lanes 3–4). In
serum-stimulated cells, the amount of NCK1 in the material
immunoprecipitated with eIF2b WT and S(2,67)D mutants was
higher relative to the amounts of NCK1 co-immunoprecipitated
with S(2,67)A and TOS eIF2b mutants (Fig. 5b; lanes 2 and
5 versus lanes 3 and 4). Torin1 decreased NCK1:WT eIF2b but not
NCK1:S(2,67)D eIF2b co-immunoprecipitation (Fig. 5c; lane 2
versus 5). We showed that the loss of PTEN attenuates the effects
of CK2 inhibition on eIF2b phosphorylation (Fig. 2e).
Consistently, CX-4945 reduced WT eIF2b phosphorylation and
NCK1:WT eIF2b association after 1 h in HCT116 PTEN þ / þ cells,
whereas 1-h exposure to CX-4945 was insufﬁcient to decrease
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eIF2b mediates effects of mTOR and CK2 on proliferation. Our
results indicate that eIF2b phosphorylation mediates the effects of
mTORC1 and CK2 on TC formation and global protein synthesis.
Since global protein synthesis rates closely correlate with
proliferation rates35, we investigated whether eIF2b acts as a
mediator of the effects of mTORC1 and CK2 on proliferation of
cells expressing WT, S(2,67)A, S(2,67)D or TOS eIF2b mutants,
wherein endogenous eIF2b was depleted (Supplementary Fig. 4b).
In 10% serum, cells expressing S(2,67)A and TOS eIF2b mutants
proliferated slower than those expressing WT eIF2b, whereas
S(2,67)D eIF2b mutant-expressing cell exhibited slightly increased
proliferation relative to WT eIF2b (Fig. 5e). Anti-proliferative
effects of torin1, serum depletion or amino-acid deprivation were
markedly attenuated by S(2,67)D eIF2b mutant as compared with
WT eIF2b-expressing cells (Fig. 5e; Supplementary Fig. 6a–c). In
addition, CX-4945 strongly reduced proliferation of WT eIF2bexpressing cells while having much lesser effect on the proliferation
of cells expressing the S(2,67)D eIF2b mutant (Supplementary
Fig. 7a). These ﬁndings demonstrate that eIF2b phosphorylation
plays a major role in mediating the effects of mTORC1 and CK2
on cell proliferation.
NCK1 is thought to stimulate dephosphorylation of eIF2a via
recruitment of PP1 (ref. 32). Thus, we treated cells with salubrinal,
which inhibits eIF2a dephosphorylation by PP1 (ref. 36). In
contrast to inhibition of mTORC1 or CK2 signalling, S(2,67)D
eIF2b mutant failed to attenuate anti-proliferative effects of
salubrinal (Supplementary Fig. 7b). This was paralleled by the
inability of S(2,67)D eIF2b mutant to impede salubrinal-induced
eIF2a phosphorylation (Supplementary Fig. 7c). Moreover, induction of expression of non-phosporylatable S51A eIF2a mutant in
HT1080 cells37 abolished the stimulatory effects of S(2,67)D eIF2b
on proliferation (Supplementary Fig. 8a–c). Taken together,
these ﬁndings show that the effects of eIF2b on cellular
proliferation are mediated by eIF2a phosphorylation and put
forward a model whereby CK2 and mTORC1 bolster TC
formation via eIF2b phosphorylation, followed by the NCK1dependent dephosphorylation of eIF2a. However, additional roles
of NCK1 that lead to the inhibition of eIF2a phosphorylation, such
as NCK1-dependent inhibition of PERK38 may also play a role in
this process. Moreover, eIF2b associates with tRNAMet
(ref. 39), as
i
well as the additional translation initiation factors including eIF1
(ref. 40), eIF1A39, eIF2B41and eIF5 (ref. 42). Therefore, it is
10

Stress (for example,
TG and starvation)

Nutrients and growth factors
CK2

PTEN

mTORC1
4E-BPs
4E
P

γ

4G
4E

P
β

4A

eIF4F

eIF2α kinases

NCK1

NCK1:WT eIF2b association and WT eIF2b phosphorylation in
HCT116 PTEN  /  cells (Supplementary Fig. 5c,d). In turn, 7-h
CX-4945 treatment reduced NCK1:WT eIF2b association that was
paralleled by decreased exogenous WT eIF2b phosphorylation
(Supplementary Fig. 5d). These ﬁndings show that, at least in
part, the effects of phospho-eIF2b on phospho-eIF2a status are
mediated via recruitment of NCK1 to eIF2. We observed that
S(2,67)D eIF2b mutant antagonizes torin1-induced upregulation in
phopsho-eIF2a levels compared with all other eIF2b variants
(Fig. 3g, lane 10 versus lanes 6–9). Therefore, to further conﬁrm
that NCK1 mediates the effects of phopsho-eIF2b on eIF2a
phosphorylation, we investigated whether downregulation
of NCK1 will abolish the ability of S(2,67)D eIF2b mutant to
antagonize increase in eIF2a phosphorylation induced by
torin1. Indeed, although expression of S(2,67)D eIF2b was
sufﬁcient to antagonize induction of eIF2a phosphorylation by
torin1 in control, scrambled short interfering RNA (siRNA)transfected cells, this effect was lost in cells in which NCK1 levels
were reduced by siRNA (Fig. 5d; lane 6 versus 11). Collectively,
these data suggest a model, whereby eIF2b phosphorylation
stimulates NCK1 recruitment to eIF2, which leads to decrease in
phopsho-eIF2a levels.
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Figure 6 | Schematic representation of the proposed model for the
coordination of ternary complex (TC) and eIF4F assembly by mTOR and
CK2. On acute stimulation with nutrients, growth factors and insulin, CK2
appears to bolster mTORC1 activity, which is likely mediated via inhibition
of PTEN. This leads to phosphorylation and inactivation of 4E-BPs, thereby
facilitating eIF4F complex assembly. Simultaneously, CK2 bolsters TC
formation by phosphorylating eIF2b. Phosphorylation of eIF2b results in the
recruitment of NCK1 to eIF2, which correlates with eIF2a
dephosphorylation, likely mediated by PP1. mTORC1 also stimulates eIF2b
phosphorylation independently of CK2, which along with its established role
in inducing eIF4F levels, demonstrates that mTORC1 also may coordinate
TC and eIF4F assembly. In response to chronic increase in protein synthesis
or stress (for example, thapsigargin (TG); shown in purple), activation of
eIF2a kinases overcomes the effects of eIF2b phosphorylation on TC
recycling, thereby allowing cells to ﬁne-tune protein synthesis levels and
energy consumption and/or adapt to stress. Broken lines represent
uncertainties, such as precise hierarchy of the effects of CK2 and mTORC1
on eIF2b (Ser2) phosphorylation.

plausible that at least some of the effects of eIF2b phosphorylation
on TC recycling, protein synthesis and proliferation are mediated
via eIF2a-independent mechanisms including direct modulation of
interaction or alteration of eIF2b interaction with
eIF2b:tRNAMet
i
translation initiation factors other than eIF2 subunits.
Discussion
It has been shown that in yeast, inhibition of TOR signalling leads
to eIF2a phosphorylation via GCN2 kinase43–45. In mammals,
the PI3K/AKT/mTOR and eIF2a signalling have been linked by
multiple mechanisms that appear to be dependent on a stressor,
length of exposure to stress or proliferation status of the cell4.
These mechanisms include inhibition of PERK and GCN2 via
the mTORC2/AKT pathway and PKR via PTEN46–48. eIF2a
phosphorylation and mTORC1 have also been linked via the
catalytic subunit of protein phosphatase 6 (PP6C)49. Our study
unravels a hitherto unprecedented mechanism of translational
regulation, whereby acute activation of mTORC1 bolsters TC
formation by inducing phosphorylation of eIF2b, which in turn
stimulates the recruitment of NCK1 to eIF2, thereby leading to
eIF2a dephosphorylation (Fig. 6). In turn, constitutive activation
of mTORC1 leads to a decrease in AKT activity via activation
of S6K1-dependent negative feedback mechanism and induction
of endoplasmic reticulum stress due to chronically elevated
protein synthesis that results in induction of eIF2a kinases and
eIF2a phosphorylation50,51. Collectively, these ﬁndings suggest a
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ﬁne-tuning mechanism, whereby stimulation of mTORC1
initially leads to upregulation in TC levels to allow induction of
translation, whereas prolonged mTOR-dependent translational
activation is compensated by downregulation of TC recycling,
thereby preserving protein and energy homeostasis. Moreover,
although induction of ATF4 expression by thapsigargin was
attenuated by phosphomimetic eIF2b mutant as compared with
those expressing WT eIF2b, higher thapsigargin concentrations
were sufﬁcient to increased ATF4 levels even in phosphomimetic
S(2,67)D eIF2b mutant-expressing cells (Supplementary Fig. 5b).
This suggests that induction of stress above a certain threshold is
likely to override the inhibitory effects of eIF2b phosphorylation
on ATF4 expression, thereby antagonizing stimulatory effects of
the mTORC1/eIF2b axis on translation and proliferation and
allowing cells to rapidly adapt to stress.
We show that acute inhibition of mTORC1 in addition to
reducing translation of TOP and ‘eIF4E-sensitive’ mRNAs via
LARP1- and 4E-BP-dependent mechanisms, respectively52–56, also
upregulates translation of ‘eIF2a-sensitive’ mRNAs (for example,
ATF4) that appears to be mediated via reduction of eIF2b
phosphorylation. In contrast to endoplasmic reticulum stressors
such as thapsigargin57, acute inhibition of the mTORC1/4E-BP/
eIF4E axis has a lesser effect on global protein synthesis and is
therefore expected to only marginally effect on translation of
housekeeping mRNAs (for example, b-actin)58. Therefore,
although mTOR inhibitors and inducers of eIF2a kinases
increase eIF2a phosphorylation, their impact on the translatome
appears to be different. Notwithstanding that mTOR and eIF2a
kinase employ a range of distinct effectors, these ﬁndings further
corroborate a tenet that translation regulation under acute stress or
stress recovery is achieved via the cross-talk between the mTOR
and eIF2a kinase pathways. Moreover, the complexity of cross-talk
between mTOR and eIF2a kinases is further illustrated by studies
showing that although we observe translational activation of ATF4
mRNA after 4 h, it is known that prolonged treatment with mTOR
inhibitors (412 h) suppresses ATF4 expression at the level of
transcription59. Future studies are however required to decipher
molecular underpinnings of mTOR/eIF2a kinase cross-talk and its
role in stress response.
CK2 and mTORC1 appear to phosphorylate overlapping sites
on human eIF2b, namely, Ser2 and Ser67. Strikingly, the effects of
mTORC1 on phosphorylation of eIF2b on Ser2 are affected by the
changes in CK2 activity and vice versa CK2 stimulation of Ser2
eIF2b phosphorylation is attenuated in cells wherein CK2
signalling is uncoupled from mTOR. These observations suggest
a complex relationship between CK2 and mTOR in regulating
eIF2b phosphorylation. Intriguingly, inspection of publicly available mass spectrometry data indicates the existence of additional
phospho-sites on eIF2b that appear to be targeted by mTORC1
and likely CK2 (Ser105 and Thr111)60–62. These additional
phospho-acceptor sites on eIF2b may therefore act as priming
sites for Ser2 phosphorylation. This may explain delayed effects of
mTOR and CK2 inhibitors on Ser2 eIF2b phosphorylation in cells
in which CK2 is overexpressed, or wherein CK2 is uncoupled from
mTORC1, respectively. However, future studies are required to
determine the precise hierarchy of mTORC1- and CK2-dependent
eIF2b phosphorylation.
Our results show that eIF2b phosphorylation-dependent
stimulation of TC formation is synchronized with eIF4F complex
assembly, which is mediated by CK2 and mTORC1. Inactivation of
4E-BPs by mTORC1-dependent phosphorylation stimulates eIF4F
complex assembly1, whereas mTORC1-mediated phosphorylation
of eIF2b appears to simultaneously facilitate TC recycling. CK2
also appears to bolster TC assembly via direct phosphorylation of
eIF2b, which is consistent with previous ﬁndings showing that
decreased CK2 activity coincides with increased eIF2a

phosphorylation and elevated CHOP expression63. At the same
time, CK2 bolsters 4E-BP phosphorylation by activating mTORC1,
which at least in part is mediated via inhibition of PTEN.
Since dysregulated mTORC1 and CK2 signalling underpin a
number of diseases characterized by aberrant protein synthesis and
proliferation including cancer, our ﬁndings suggest that eIF2b
phosphorylation may also play a prominent role in these
pathologies.
Methods
Cell culture and compounds. HEK293E and MCF7 cells were obtained from
American Type Culture Collection (ATCC) and maintained in DMEM and RPMI1640, respectively, supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% L-glutamine (all from Wisent Bio Products). HCT116 PTEN þ / þ
and PTEN  /  cells were obtained from Dr Waldman19 and maintained in DMEM
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1%
L-glutamine. U2OS cells that overexpress CK2a/b under the control of TetOFF
system16 were maintained in DMEM supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, 1% L-glutamine and 1.5 mg ml  1 tetracycline (SigmaAldrich) to suppress CK2a/b expression. CK2a/b expression was induced by
washing the cells three times in 1  PBS, and incubating them in tetracycline-free
media for 16 h before treating cells as indicated in ﬁgure legends. HT1080 cells
expressing eIF2a WT and HA-eIF2a KI37 were maintained in DMEM supplemented
with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% L-glutamine in the
presence of 2 mg ml  1 puromycin (Sigma-Aldrich). TSC WT and knockout MEFs
were maintained in DMEM supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin and 1% L-glutamine. All culture media and reagents were
obtained from Wisent Inc, unless speciﬁed. All cell lines were maintained in 5% CO2
at 37 °C. Micoplasma contamination was excluded using Mycoplasma PCR
Detection Kit (Applied Biological Materials Inc). Where indicated, cells were treated
with 250 nM torin1 (Tocris), 50 nM rapamycin (Calbiochem), 3 mM Ku-0063794
(Tocris), 10–50 mM CX-4945 (Adooq Bioscience), 1 mM thapsigargin
(Sigma-Aldrich) or 1 mM salubrinal (Tocris). All drugs were stored in aliquots at
 80 °C in DMSO for no longer than 6 months, and equal volume of DMSO was
used as a vehicle control. HEK293E cells were freshly obtained from ATCC before
the experiments (293 c18 (ATCC CRL-10852)), whereas the rest of the cell lines used
were veriﬁed by proﬁling 17 short tandem repeat (STR) and 1 gender determining
loci using ATCC Cell Line Authentication Service and the results were as following:
HCT116 (94% match to ATCC HCT116 # CCL-247): D5S818 (10, 11 versus
10, 11); D13S317 (10, 12 versus 10, 12); D7S820 (11, 12 versus 11, 12); D16S539
(11, 12, 13, 14 versus 11, 13); vWA (17, 21, 22, 23 versus 17, 22); THO1 (8, 9 versus
8,9); AMEL (X versus XY); TPOX (8, 9 versus 8, 9), CSF1PO (7, 10 versus 7, 10).
MCF7 (100% match to ATCC MCF7 cells # HTB-22): D5S818 (11, 12 versus
11, 12); D13S317 (11 versus 11); D7S820 (8, 9 versus 8, 9); D16S539 (11, 12 versus
11, 12); vWA (14, 15 versus 14, 15); THO1 (6 versus 6); AMEL (X versus X);
TPOX (9, 12 versus 9, 12), CSF1PO (10 versus 10).
U2OS (93% match to ATCC U2OS cells # HTB-96): D5S818 (8, 11 versus 11);
D13S317 (13 versus 13); D7S820 (11, 12 versus 11, 12); D16S539 (11 versus 11, 12);
vWA (14, 18 versus 14, 18); THO1 (6, 9.3 versus 6, 9.3); AMEL (X versus X);
TPOX (11, 12 versus 11, 12), CSF1PO (12, 13 versus 13).
HT1080 (93% match to ATCC HT1080 cells # CCL-121): D5S818 (11, 13 versus
11, 13); D13S317 (14 versus 12, 14); D7S820 (9, 10 versus 9, 10); D16S539
(9, 12 versus 9, 12); vWA (14, 19 versus 14, 19); THO1 (6 versus 6); AMEL
(X, Y versus X, Y); TPOX (8 versus 8), CSF1PO (12 versus 12).
TSC2 WT and knockout MEFs were generated by Kwiatkowski’s group and
obtained from Sonenberg’s lab.
Constructs and recombinant proteins. Human eIF2b was subcloned from pOTB7
vector (provided by Dr Kimchi) in pEF-FLAG vector (generously provided by
Dr Ronai) using SalI and BamHI enzymes. Ser2 and Ser67 were mutated into an
alanine (A) or aspartate (D) and phenylalanine 89 into an alanine (TOS mutant)
using Quick-Change Site-Directed Mutagenesis (Agilent Technologies). For stable
expression in mammalian cells, FLAG-eIF2b variants were subcloned in pWPI-GFP
vector (Addgene) using PmeI enzyme. To produce the recombinant proteins, eIF2b
was subcloned in pGEX-6p-1 vector (GE Healthcare Life Sciences) using BamHI and
EcoRI. Recombinant proteins were puriﬁed as follows: 50 ml of BL21 (DE3)
competent E. coli transformed by heat shock with B300 ng of pGEX-6p-1-eIF2b
constructs (encoding WT or S(2,67)A, TOS and S(2,67)D eIF2b mutants) was
induced with isopropylthiogalactoside for 3 h and then lysed in lysis buffer (50 mM
Tris HCl (pH 7.5), 300 mM NaCl, 10 mM TCEP (tris(2-carboxyethyl)phosphine;
Sigma-Aldrich)). Lysates were incubated with 20 ml of Glutathione Sepharose 4B
(GE Healthcare Life Sciences) for 1 h at 4 °C and then washed twice with lysis buffer
supplemented with 5% glycerol and 0.1% NP-40, and 700 mM NaCl. Recombinant
proteins were then washed once in buffer B (20 mM Tris HCl pH 7.5, 100 mM
KCl, 0.1 mM EDTA, 5% glycerol). For in vitro translation and circular dichroism
experiments, glutathione S-transferase (GST) tag was removed with PreScission
protease (GE Healthcare Life Sciences). GST tag was not removed for the in vitro
kinase assay.
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siRNA, lentiviral shRNA and generation of cell lines expressing eIF2b variants
depleted of endogenous eIF2b. Scrambled control (NS1) and siRNA targeting
human NCK1 (50 -AACAUCCAUUACAUCUCCUUUCUCGAA-30 ) were obtained
from Integrated DNA Technologies. siRNA were transfected using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions at the ﬁnal concentration of 10 nM. Cells were lysed 72 h post transfection in RIPA buffer and
analysed by western blotting. Lentiviral vectors carrying shRNA targeting human
raptor (plasmid 1857), human rictor (plasmid 1854) and the non-target shRNA
control (plasmid 1864) were from Addgene. shRNAs targeting human eIF2b
(TRCN0000291996) and scrambled control (SHC002) were from Sigma-Aldrich
(Mission collection). Vectors encoding shRNAs (7 mg) were co-transfected into
5  106 HEK293T cells with 7 mg of each lentivirus packaging plasmids PLP1, PLP2
and PLP-VSVG (Invitrogen). Viral supernatant was collected 48 h post transfection,
ﬁltered through a Mixed Cellulose Ester ﬁlter (0.45 mm, Fisher Scientiﬁc), mixed in
1:1 ratio with growth media and added to cells for 24 h. Infection was carried out in
the presence of 8 mg ml  1 of polybrene (Sigma-Aldrich). Forty-eight hours post
infection, cells were selected and maintained in full growth media supplemented with
5 mg ml  1 puromycin. To generate cells lines expressing FLAG-eIF2b variants,
viruses were generated and HEK293E cells were infected as described above.
Expression of shRNA-insensitive eIF2b variants was monitored 72 h post infection
by western blotting and cells were then infected with viruses carrying shRNA
targeting eIF2b or scrambled control. Forty-eight hours post infection, cells were
selected with 2 mg ml  1 puromycin as described above and expression of indicated
exogenous eIF2b variants as well as depletion of endogenous eIF2b was determined
by western blotting (Supplementary Fig. 4b).
Antibodies and western blotting. For western blotting, cells were scraped in
1  PBS (pH 7.4), centrifuged and lysed in RIPA buffer (10 mM Tris (pH 7.3),
1% (w/v) Na-deoxycholate, 1% (v/v) Triton, 150 mM NaCl, 1 mM EDTA, 50 mM
NaF, 10 mM b-glycerophosphate and protease inhibitors) supplemented with
complete protease inhibitors (Roche). Whole-cell protein extracts (10–60 mg) were
analysed by SDS–polyacrylamide gel electrophoresis (SDS–PAGE; 6–15%
polyacrylamide gels were used depending on molecular weight of analysed proteins) and transferred to nitrocellulose membrane (Bio-Rad) using wet transfer
apparatus (Cleaver). Following antibodies were diluted as indicated in 5% (w/v)
bovine serum albumin (Sigma-Aldrich) in 1  TBS-Tween 20 and incubated
overnight at 4 °C: anti-eIF2a (L57A5) #2103 (1:1,000), anti-p-eIF2a (S51) #9721
(1:1,000), anti-4E-BP1(53H11) #9644 (1:2000), anti-p-4E-BP1/2 (S37/46)(236B4)
#2855 (1:1,000), anti-p-4E-BP1(S65)(174A9) #9456 (1:1,000), anti-p70 S6 kinase
#9202 (1:1,000), anti-p-p70 S6K1/2 (T389/388) #9205 (1:1,000), anti-p-rpS6 (S240/
244) #2215 (1:1,000), anti-p-AKT (S473) #9271 (1:1,000), anti-AKT (pan) (C67E7)
#4691 (1:1,000), anti-NCK1 (15B9) #2319 (1:1,000), anti-raptor (24C12) #2280
dilution (1:1,000), anti-rictor #2140 (1:1,000); anti-PTEN (138G6) #9559 (1:1,000),
anti-mTOR (7C10) #2983 (1:1,000), anti-PRAS40 #2610 (1:1,000), anti-p-PTEN
(S380;T382/383) (44A7) #9549 (1:1,000), anti-PERK # 5683 (1:1,000), anti-p-PKR
(T446) # 3076 (1:1,000), anti-eIF4G1 #2858 (1:1,000) and anti-Myc-Tag #2276
(1:1,000) all from Cell Signaling Technologies; anti-TSC2 sc-893 (1:500), antieIF2b (P-3) #sc-9978 (1:1,000), anti-ATF4 (CREB-2) C-20 #sc-200 (1:1,000), rpS6
(C-8) #sc-74459 (1:2,000) and anti-p-PERK (T981) sc-32577 (1:500) all from Santa
Cruz Biotechnologies; anti-eEF1d #A301–685A (1:2,000) and eIF2Bd #A302–982A
(1:1,000) both from Bethyl Labs; anti-FLAG(M2) #F3165 (1:5,000) and anti-b-actin
(AC15) #A1978 (1:5,000) both from Sigma; anti-eIF4E #610269 (1:1,000) from BD
Biosciences; anti- #ab9110 (1:2,000) from Abcam; anti-PKR (F9)64 (1:1,000),
anti-p-eIF2b (S2) (1:10000), anti-p-eEF1d (1:10,000)65 and anti-CK2a (1:1000)
were generated in Litchﬁeld’s lab. Secondary antibodies (Amersham) were used at
1:10,000, and signals were revealed by chemiluminescence (ECL, GE Healthcare).
Where possible, membranes were stripped and reprobed with indicated antibodies.
In the cases where this was not possible (for example, wherein the phospho and
total antibodies or antibodies recognizing same proteins were used and signiﬁcant
signal remained on the membrane after striping), same lysates were ran
simultaneously on duplicate gels, and probed with phospho and total antibodies.
Each experiment was performed at least twice independently and the representative
data are shown. X-ray ﬁlms and/or ECL scans of whole membranes are shown in
Supplementary Fig. 10. Although we trust that western blotting should be used for
qualitative rather than quantitative measurements, as requested by reviewers, we
performed densitometric analysis using ImageJ (W. S. Rasband, ImageJ; National
Institutes of Health, Bethesda, MD). The resulting data were log2 transformed,
normalized per replicate and to the mean of the control, and analysed using
analysis of variance in R (r-project.org) (Supplementary Fig. 9).
In vitro kinase assay. For in vitro kinase assay, HEK293E cells were transfected in
a 10-cm Petri dish with 7 mg of HA-Raptor using Lipofectamine 2000 (Invitrogen)
according to manufacturer’s instruction. HA-immunoprecipitation was performed
in CHAPS buffer (40 mM HEPES KOH (pH 7.4), 2 mM EDTA, 10 mM sodium
pyrophosphate, 0.1 M NaCl, 0.3% CHAPS), washed twice with CHAPS buffer and
once in CHAPS buffer supplemented with 0.4 M NaCl. Beads were then washed
twice in kinase buffer (25 mM HEPES KOH (pH 7.5), 50 mM KCl, 10 mM MgCl2)
and resuspended in 40 ml of kinase buffer. One-sixth of the immunoporecipitated
material and 1 mg of recombinant GST-eIF2b variants were used per reaction.
Reaction was carried out at 30 °C for 30 min in a ﬁnal volume of 50 ml, in the
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presence of 100 mM ATP, 0.5 ml of 10 mCi ml  1 of 32P-gATP (Perkin Elmer) and
1  of kinase buffer. Reactions were stopped with 4  Laemmli Sample Buffer
and samples were loaded on a 10% SDS–PAGE gel. SDS–PAGE gel was then
stained with Coomassie brilliant blue R-250, dried for 2 h at 80 °C and the
phosphorylation was measured by 32P incorporation using Storm 860 Molecular
Imager. Each experiment was carried out at least in two independent replicates.
Reporter translation assays. In vitro translation assay and in vitro transcription
of the reporter renilla mRNA were performed by depleting eIF2 using anti-eIF2b
antibody. eIF2b was ﬁrst linked to 10 ml of protein G agarose beads in 1  at 4 °C
for 2 h. Beads and antibody were then washed twice in PBS and twice in buffer D
(25 mM HEPES KOH (pH 7.3), 50 mM KCl, 75 mM KOAc, 2 mM MgCl2). After
the last wash, buffer D was removed and the antibody-conjugated beads were
incubated with nuclease-treated RRL for 2 h at 4 °C. Puriﬁed eIF2a and eIF2g
lacking the eIF2b subunit were kindly provided by Yuri Svitkin from Sonenberg’s
laboratory. For translation reaction, 50 ng of the reporter mRNA was added to 7 ml
of RLL in a ﬁnal volume of 10 ml. Titration experiments were performed adding
increasing amount of eIF2 b recombinant proteins (40, 80, 160 and 270 ng). In
eIF2-depleted RRL, eIF2 was reconstituted by adding 37.5 or 75 ng of puriﬁed
eIF2a/g subunits and 37.5 or 75 ng of recombinant eIF2b. Translation reaction was
carried out at 30 °C for 30 min and stopped adding equal volume of 2  PBS.
Renilla expression was measured in 3 ml of RRL with 50 ml of Renilla Luciferase
Assay system (Promega).
Translation of the reporter mRNAs harbouring 50 UTR of human ATF4 (ref. 28).
was monitored by dual-luciferase assay. HEK293E cells expressing eIF2b variants
were seeded in a 10-cm Petri dish and transfected with a mixture of 600 ng of
pRenilla (provided by Dr Sonenberg) and 1.2 mg of p50 UTR ATF4-ﬁreﬂy luciferase
reporter vectors28 using Lipofectamin 2000 (Invitrogen) according to manufacturer’s
instruction. Twenty-four hours post transfection, 9  105 cells were seeded in a
six-well plate in triplicate and the luciferase assay was performed at 48 h post
transfection with cells at 80% conﬂuency. Cells were collected in Passive Lysis Buffer,
and ﬁreﬂy and renilla luciferase activity was measured using the Dual-luciferase
Reporter Assay kit (Promega) according to the manufacturer’s instructions.
Experiments were repeated three times independently (n ¼ 3), whereby each
biological replicate consisted of a technical duplicate.
Genome-wide polysome proﬁling and RT–qPCR. Polysome proﬁling6 was
performed in four independent biological replicates. MCF7 cells were seeded in a
15-cm Petri dish, serum starved for 16 h (‘control’) and then treated with 4.2 nM of
recombinant human insulin (Sigma-Aldrich) for 4 h alone (‘insulin’) or in
combination with 250 nM torin1 (‘insulin þ torin1’). Cells were collected at 80%
conﬂuency and lysed in hypotonic lysis buffer (5 mM Tris HCl pH (7.5), 2.5 mM
MgCl2, 1.5 mM KCl, 100 mg ml  1 cycloheximide, 2 mM dithiothreitol (DTT), 0.5%
Triton, 0.5% sodium deoxycholate). Ten per cent of the lysates was saved to isolate
cytoplasmic mRNA. The amount of RNA in each lysate was measured at 254 nm and
12 ODs were loaded on 5–50% sucrose gradients generated using Gradient Master
(Biocomp) and subjected to ultracentrifugation (SW41 rotor; Beckman 36,000, 2 h
and 4 °C). Sucrose gradients were fractionated by displacement by 60% sucrose/
0.01% bromphenol blue, using ISCO Foxy fraction collector (35 s for each
fraction ¼ 750 ml per fraction) equipped with a ultraviolet lamp for continuous
absorbance monitoring. Fractions were ﬂash-frozen immediately after fractionation
and stored at  80 °C. RNA was isolated with Trizol (Thermo Fisher Scientiﬁc)
according to the manufacturer’s instruction. For microarray analysis, fractions
corresponding to heavy polysomes (more than three ribsomes) were pooled (Fig. 1a).
RNA was submitted to the Bioinformatics and Expression analysis core facility at
Karolinska Institutet. RNA quality was assessed using an Agilent 2100 Bioanalyzer
(Agilent Technologies) and complementary DNA was generated and hybridized
onto the Affymetrix Human Gene 1.1 ST Array. The oligo package version 1.30.0
was used to summarize and normalize expression data using robust multiarray
average (rma) in R version 3.1.1 (www.r-project.org) and bioconductor version 3.0.
We used updated probe set deﬁnitions66 as these showed improved precision and
accuracy67. We assessed the reproducibility using principal component analysis.
Samples clustered according to RNA (cytosolic or polysome associated) and
experimental group (control, insulin or insulin þ torin1) indicating good
reproducibility. We obtained mean expression levels for each treatment and RNA
combination. These were then used to calculate mean log2 fold changes between
insulin þ torin1 versus insulin and insulin versus control for each RNA separately
(polysome associated or cytosolic). Two-sided Wilcoxon rank-sum test was used to
compare differences in fold changes between mRNAs whose translation was
stimulated by phosphorylation of eIF2a5 to those that were not using data from
polysome-associated mRNA or cytoplasmic mRNA separately. Data are displayed in
Fig. 1. Raw and processed data are available at the Gene Expression Omnibus
(GSE76766). For reverse transcriptase–quantitative PCRs (RT–qPCRs), RNA was
extracted using Trizol according to the manufacturer’s instructions. RT–qPCRs were
performed using SuperScript III Reverse Transcriptase, followed by Fast SYBR Green
Mastermix (both from Invitrogen), according to the manufacturer’s instructions.
Analyses were carried out using relative standard curve method as described in
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/
generaldocuments/cms_040980.pdf. Experiments were performed at least in
independent duplicates (n ¼ 2), whereby every sample was analysed in a technical
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triplicate. Primers were designed using NCBI Primer-BLAST (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/) such that Tm was between 57 and 63 °C, Tm
difference was o3 °C and that primer pairs were separated by at least one intron.
Primers were obtained from Integrated DNA Technologies, and their sequences and
size of the amplicons are listed below:
ATF4 (NM_001675.4, NM_182810.2); Amplicon ¼ 226 nt
Human ATF4-Forward 50 -TCAAACCTCATGGGTTCTCC-30
Human ATF4-Reverse 50 -GTGTCATCCAACGTGGTCAG-30
Note: these primers recognize Homo sapiens ATF4, transcript variant 1, mRNA
(NM_001675.4) and Homo sapiens ATF4, transcript variant 2, mRNA
(NM_182810.2), both of which contain inhibitory uORFs and are translationally
activated when eIF2a phosphorylation is induced and encode identical protein68,69.
PCR product is of same size irrespective which variant is ampliﬁed.
b-Actin (ACTB; NM_001101.3); Amplicon ¼ 163 nt
Actin HF 50 - ACCACACCTTCTACAATGAGC-30
Actin HR 50 - GATAGCACAGCCTGGATAGC-30
Metabolic (35S-methionine/cysteine) labelling. For 35S-methionine/cysteine
labelling, HEK293E cells were seeded in six-well plates, serum starved for 16 h and
then deprived of methionine and cysteine for an additional 2 h using DMEM
without the above amino acids (Gibco). Cells were then treated with 10% dialysed
serum containing 10 mCi ml  1 of 35S-Met/Cys (Perkin Elmer) and 250 nM of
torin1 were indicated. Cells were lysed in RIPA buffer without SDS and 10 ml of the
protein extract measured by LS6500 Multi Purpose Scintillation Counter (Beckman
Coulter). Experiments were performed in independent triplicates (n ¼ 3) each of
which was performed in a technical duplicate.
Cap (m7GTP) pull-down assay. MCF7 and HCT116 cells were treated as
described in Supplementary Fig. 1a, and lysed in two volumes of buffer B (50 mM
MOPS KOH (pH 7.4), 100 mM NaCl, 50 mM NaF 2 mM EDTA, 2 mM EGTA,
1% NP-40, 1% sodium deoxycholate, 7 mM b-mercaptoethanol, protease inhibitors
and phosphatase inhibitor cocktail 1 (Sigma-Aldrich)) on ice for 15 min with
sporadic vortexing. Extracts were cleared by centrifugation (16,100g for 10 min at
4 °C). m7GTP-Agarose beads (g-aminohexyl-m7GTP-agarose; Jena Biosciences,
Jena, Germany) were equilibrated in buffer C (50 mM MOPS KOH (pH 7.4),
100 mM NaCl, 50 mM NaF, 0.5 mM EDTA, 0.5 mM EGTA, 7 mM b-mercaptoethanol, 2 mM benzamidine or 0.5 mM PMSF, 1 mM Na3VO4 and 0.1 mM GTP
(Sigma-Aldrich)). After equilibration, lysates were diluted (B500 mg of total cell
protein) to 1 ml with buffer C (in a 2-ml tube) and incubated with equilibrated
m7GTP-Agarose beads (B50 ml of 50% slurry) for 20 min at 4 °C end-over-end
rotation. Ten per cent of the lysate was used as the input. The beads were collected
by centrifugation (500g for 5 min at 4 °C) and washed four times with 1.5 ml of
buffer C. Bound proteins were eluted with 0.2 mM m7GTP, resuspended in
SDS–PAGE loading buffer and analysed by western blotting along with the inputs.
Experiments were performed in independent duplicate.
Co-immunoprecipitations, sqRT–PCR and qRT–PCR analyses. Raptor
immunopreciptations were carried out using an anti-raptor antibody (Millipore).
HEK293E cells were serum starved overnight and then treated as described in
ﬁgure legends. Cells were collected in CHAPS buffer (0.2% CHAPS, 40 mM
HEPES (pH 7.4), 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM
b-glycerophosphate, 50 mM NaF, 1 mM DTT). Immunoprecipitation was
performed in the presence of 0.5 mg ml  1 reversible crosslinker 3,30 -dithiobis
(sulfosuccinimidylpropionate) DTTSP (Life Technologies). Two microlitres of
anti-raptor antibody (Millipore, 1:500) and 30 ml of protein G-sepharose 50% slurry
(Millipore) were equilibrated in CHAPS buffer and incubated in 100 ml of CHAPS
buffer for 30 min at 4 °C, washed followed by incubation with 1 mg of the lysates
for 4 h at 4 °C, with end-to-end rotation. Beads were washed four times with 1 ml
of ice-cold CHAPS buffer and collected by centrifugation (500g for 2 min at 4 °C).
Fifty microlitres of beads were resuspended in the sample buffer, boiled and
analysed by western blotting.
For endogenous eIF2b immunoprecipitations, cells were collected by scraping,
washed three times in ice-cold PBS (1,200 r.p.m. for 5 min at 4 °C) and lysed in
NET-2 buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 2 mM MgOAc, 0.1% NP-40,
1 mM DTT, 1  EDTA-free protease inhibitors (Roche)) by 3  10-s bursts using
microtip at power 6 on ice. The lysates were spun for 10 min/16,100g at 4 °C. An
amount of 1 mg ml  1 of the protein was incubated with 40 ml of the NET-2 buffer
equilibrated protein A sepharose beads (Millipore; 30 min at 4 ° C; end-over-end
rotation) on which the supernatant was split in two, set at 500 mg ml  1 and
incubated for 2 h at 4 ° C (end-over-end rotation) with either eIF2b antibody (P-3)
#sc-9978 from Santa Cruz Biotechnologies or the appropriate IgG1 control
(#M5284; Sigma; 2 mg of the antibody/IgG per 100–500 mg of total cell protein). On
the incubation with the antibody, protein A sepharose beads were added
(B30 ml mg  1 of antibody), and the incubation was carried out for the additional
2 h at 4 °C. After the immunoprecipitated beads were washed one time with NET-2
buffer containing 300 mM NaCl and ﬁve times with NET-2 buffer containing
150 mM NaCl. Beads were eluted in Laemmli buffer by boiling and eluates were
analysed by western blotting.

Anti-FLAG immunopreciptiations were carried out using anti-FLAG(M2)
#F3165 and the same concentration of isotype-matched mouse IgG1 antibody
#M5284 as a control (both from Sigma). Two micrograms of the antibody/IgG per
100–500 mg of total cell protein were used. HEK293E cells were seeded in a 15-cm
Petri dish and collected at 80% conﬂuency in 1.5 ml eIF2-IP buffer (20 mM Tris
HCl (pH 7.5), 100 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 5 mM EGTA, 1 mM
DTT, 20 mM NaF, 0.1 mM Na3VO4, 20 mM b-glycerophosphate, 0.3% CHAPS).
FLAG-eIF2b variants were immunoprecipitated using 10 ml FLAG-agarose beads
(Sigma-Aldrich), previously equilibrated in eIF2-IP buffer, for 90 min at 4 °C.
Immunoprecipitated material was washed twice in 1 ml of eIF2-IP buffer
(4,000 r.p.m. for 1 min at 4 °C). FLAG-eIF2b was eluted three times with
FLAG-eluting peptide at 4 °C according to the manufacturer’s instructions.
To monitor eIF2:tRNA binding, half of the immunoprecipitated material was
analysed by western blotting and half was used to extract RNA using Trizol.
Analysis of tRNAMet
and tRNALys was performed by semi-quantitative reverse
i
transcription–PCR (sqRT–PCR) using OneStep RT–PCR kit (Qiagen) and
quantitative reverse transcription–PCR (qRT–PCR) using Power SYBR Green
RNA-to-Ct 1-Step Kit (Applied Bioscience) according to the manufacturer’s
instruction. Following primers were used:
tRNAMet
_; Amplicon: 71
i
tRNAMet
_Fwd: 50 -AGCAGAGTGGCGCAGCGGAAGCGTGCT-30
i
Met
tRNAi _Rev: 50 -TAGCAGAGGATGGTTTAGATCCATC-30
tRNALys_; Amplicon: 72
tRNALys_Fwd: 50 -GCCCGGATAGCTCAGTCGGTAGA-30
tRNALys_Rev: 50 -CGCCCGAACAGGGACTTGAACC-30
sqRT–PCR reactions were carried out using the following conditions: annealing
T ¼ 60 °C for 30 s, denaturation T ¼ 94 ° C for 1 min and elongation T ¼ 72 °C for
1 min for 30 cycles. qRT–PCR reactions were carried out under the following
conditions: reverse transcription: 48 °C for 30 min; activation of DNA polymerase:
95 °C for 10 min; 40 cycles: denature 95 °C for 15 s; anneal/extend 60 °C for 1 min.
All immunoprecipitation/PCR experiments were carried out at least in
independent duplicates.
Proliferation assay. HEK293E cells (1  104) expressing eIF2b variants, in which
endogenous eIF2b was depleted by shRNA (Supplementary Fig. 4b), were seeded in
a 96-well plate and treated as indicated in ﬁgure legends. For amino-acid deprivation experiments, 5  104 cells were seeded in a 96-well plate and maintained in
DMEM without amino acids (Gibco) supplemented with 10% dialysed serum for 6
and 18 h (Invitrogen). Proliferation rate was determined using Cell Proliferation
ELISA BrdU kit (Roche). Absorbance at 370 nm (reference wavelength 492 nm)
was measured using a Benchmark Plus microplate reader (Bio-Rad). The experiments were performed in independent triplicate (n ¼ 3), with four technical
replicates per biological replicate.
Circular dichroism. Far-ultraviolet circular dichroism spectra of the eIF2b WT
and S(2,67)A, TOS and S(2,67)D eIF2b mutants (4 mg in 100 ml of 10 mM
phosphate buffer (pH 7.2), 50 mM NaCl) puriﬁed as described in the ‘Constructs
and recombinant proteins’ section were continuously detected from 197 to
250 nm using Chirascan CD Spectrometer (Applied Photophysics). The
measurements were carried out in using a 1-mm path-length cuvette (Hellma) at
room temperature using a 1-nm bandwidth. For each sample, two spectra were
collected and averaged. The spectral contribution of the buffer was corrected for by
subtraction.
Identiﬁcation of TOS motifs. TOS motifs (F E/D/V M/I/L D/E/V I/E/L)
were identiﬁed in RefSeq proteins using pattern matching70 in both mouse
and human proteins. For genes encoding for proteins with multiple
isoforms containing a TOS motif, only one isoform was reported. Human
proteins with TOS motifs were reported with a comparison with TOS
motifs in mouse proteins (human and mouse proteins were linked using gene
symbols).
Separation of cellular extracts on 15–35% sucrose gradients. For ribosome
proﬁles shown in Supplementary Fig. 3e, 80% conﬂuent HEK293E cells that stably
express exogenous FLAG-eIF2b variants and are depleted of endogenous eIF2b
(Supplementary Fig. 4B) were collected in buffer containing 30 mM Tris HCl
(pH 7.5), 100 mM NaCl, 2.5 mM MgCl2, 0.1% Na-deoxycholate, 100 mg ml  1
cycloheximide, 1 mM DTT, 20 mM NaF, 0.1 mM Na3VO4 and 20 mM
b-glycerophosphate. Five ODs (at 254 nm) were loaded onto 15–35% sucrose
gradients buffered with 20 mM HEPES (pH 7.6), 100 mM KCl, 5 mM
MgCl2, 100 mg ml  1 cycloheximide, 1  protease inhibitor cocktail
(EDTA free), 100 U ml  1 RNase inhibitor (Ambion) and subjected to
ultracentrifugation (SW41 rotor; Beckman 39,000, 4 h 30 min at 4 °C). Absorbance
proﬁles were detected as described in the section entitled ‘Genome-wide
polysome proﬁling and qRT–PCR’. Area under the monosome (80S) peak areas
were integrated using ImageJ, and presented as 80S vector control versus indicated
eIF2b variants.
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